PACB

PACB

Pacific Biosciences of California Inc. Common Stock

$1.160+0.000 (0.000%)

Prix en Temps Réel

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.160

Haut

$1.160

Bas

$1.160

Volume

8.25M

Fondamentaux de l'Entreprise

Statistiques de Trading

Actualités Connexes

PR Newswire

Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading...

Voir plus
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
GlobeNewswire

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the

Voir plus
PacBio to Present at Upcoming Investor Conferences
GlobeNewswire

PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized

Voir plus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene
Analyst Upgrades

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Piper Sandler analyst David Westenberg maintains Pacific Biosciences with a Neutral and lowers the price target from $2 to $1.25.

Voir plus
Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25
Analyst Upgrades

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

Stephens & Co. analyst Mason Carrico reiterates Pacific Biosciences with a Overweight and maintains $1.8 price target.

Voir plus
Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target